[Table/Fig-4]:
Efficacy and safety endpoints in enoxaparin and fondaparinux groups at day 9 and 30. *p>0.05
| Study Out come | Enoxaparin (n 90) | Fondaparinux(n90) | ||
|---|---|---|---|---|
| Day 9 | Day 30 | Day 9 | Day 30 | |
| Recovery | 81(90%) | 76(84.4%) | 85(94.4%) | 87(96.7%) |
| Recurrent MI/Angina | 6(6.6%) | 4(4.4%) | 4(4.4%) | 3(3.3%) |
| Haemorrhage | 3(3.3%) | 10(11.1%) | 1(1.1%) | 0* |
| Death | 0 | 0 | 0 | 0 |